News summary

Eos SENOLYTIX invites the public to keep pace with Speedy

Source: Longevity Technology • Published: 22 Oct 2026, 07:25

Summarized by Masters of Longevity from Longevity Technology.

A behind-the-scenes feature on a longevity company’s daily public tracking of a single long‑lived treated mouse, inviting curiosity about their live‑data approach.

Eos SENOLYTIX invites the public to keep pace with Speedy
Key Takeaways
  • Eos SENOLYTIX is posting daily 30-second clips and status updates for a 167-week-old treated mouse named Speedy.
  • Speedy received weekly PTC-2105 injections from 80 weeks and outlived the last saline control, which died at 137 weeks.
  • In a separate study, a PTC-2105–treated mouse on a high-fat diet lived to 164 weeks, outlasting semaglutide and saline controls.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.